Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Sep 19, 2019 1:48pm
168 Views
Post# 30144324

RE:RE:RE:RE:RE:RE:RE:RE:RE:Still can't believe......

RE:RE:RE:RE:RE:RE:RE:RE:RE:Still can't believe......
Dec. 2017 (20 months ago), Mackie came up with this speculative buy (IMV) with a target @2.80$

IMV now trades 4.05$, with a 52 Week range between 3.06$ and 8.49$.  Market valuation of 220M$(50M TSO) for 8 Ph. 2s with Keytruda on similar indications like ours.

All this for something that comes in support of Keytruda.

And for little clowns that lack perspective when they whine about TLT @0.25$, IMV was IPOed in 2010, in a @3.30$-4.60$ range in first weeks of trading, 10-15x higher than us.  So we're kind of priviledged to have this current entry price range.  At 1$, we already equal IMV's current market valuation.  May 2018 was IMV's highest share price (8.70$).

 

2017-12-08 · Mackie reckons the firm is 'breaking ... says Mackie, as it rates stock 'speculative buy ... Broker Mackie repeated a 'speculative buy' stance on ...


Mackie reckons the firm is 'breaking ground' and targets C$2.80 for the shares..

Under this collaboration, IMV and The Wistar Institute will partner to develop a targeted T cell therapy against the common BRAF cancer mutation, based on peptides identified by the Herlyn lab. Mutations in this gene are the most frequently identified cancer-causing mutations in melanoma and have been identified in various other cancers, including non-Hodgkin lymphoma, colorectal cancer, thyroid cancer, and non-small cell lung and ovarian carcinomas1.


_________________


Claridge - (9/19/2019 10:21:23 AM)
RE:RE:RE:RE:RE:RE:RE:RE:Still can't believe......
Goldn1 ... Contrary to you, Roger will have tried something. 

Something like trying to displace chemo. and saving lives of late-stage patients, something that big pharmas, with their big fat R&D and marketing budgets have not even came close, over the last 60 years.

You?  Bah!!!!  It's not even worth discussing ... ;-)

I assume that if you have cancer though, you'll pray to have access to what Roger will have put in place.

So it's a bit amazing some of the hypocrites we have here.  The same that fiercly don't care about public health coverages for those that cannot afford a private one but all of a sudden, they feel insulted that the founder of a disruptive technology that can displace chemo and save lives was granted options.  The same hypocrites that are in this stock for an avg, of lets say 0.40$, trying to make us beleive that they've been stolen, letting us believe this stock won't give them an amazing ROI if Ph. 1b results are replicated!!!

By the way, these stock options have been approved by the consultant that the OSC requested.  

Funny also that our same clowns (SilverT, Yajne, CaInPlap, Bungee, etc ...) silence the number of stock options bank CEOs have received, for just keeping the market shares of their banks afloat, while executing in a very stable industry.

They also silence the number of stocks options Bezos, Gates, Buffet , etc ... were granted over the years for something that doesn't even come close to saving lives with complex innovation.

And they laud Trump!  

Lolll 

_________________
goldn1 - (9/18/2019 8:54:32 PM)
RE:RE:RE:RE:RE:RE:RE:Still can't believe......

Ben Are you referring to roger when you make this quote. It's spot on... "Again, I have no morale for those that are only self-centered, only focused on money and that lack perspectives"

Bullboard Posts